CTH120 not checked

Connecta Therapeutics, S.L.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
1 active
2 in total · 2 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“15 participants will be randomized to receive CTH120 placebo hard capsules. Capsules of CTH120 matching placebo will be administered by the oral route to participants twice a day, one capsule in the morning and one capsule in the evening, at approximately the same times each day, after breakfast (morning dose) and after dinner (evening dose), with a glass of water. The evening dose will be taken…”In the company’s words, NCT07654114 on ClinicalTrials.gov
Tested for
Fragile X Syndrome (FXS), Fragile X Syndrome
Main trialPhase 2
“The purpose of this Phase IIa study is to evaluate the safety, tolerability, and effectiveness of CTH120 in adult males with Fragile X syndrome.”In the company’s words, NCT07654114 on ClinicalTrials.gov

Other drugs for Fragile X Syndrome (FXS)

All 7 drugs for Fragile X Syndrome (FXS)

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 2Recruiting May 2027 Safety, Tolerability, and Preliminary Effectiveness of CTH120 in Fragile X Syndrome
Phase 1Completed 11 Nov 2024 CTH120 First-in-Human Study: Single and Multiple Ascending Doses and Potential Food Interaction
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow CTH120

Following is part of Solo: you see every change to CTH120 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in